Nevada Pharmacy Board regulators fined three individuals and a Texas-based private membership association after peptide injections at a Las Vegas anti-aging conference sent two women to the hospital so sick they required intubation — underscoring how hard it can be to trace, test, and regulate gray-market “peptide” products used outside standard medical care.

The Move

• The Nevada Pharmacy Board levied $10,000 fines against a California physician (Kent Holtorf) and a California-licensed pharmacist (Han Bao Nguyen) for practicing in Nevada without permission.

• It fined an “integrative health coach” (Michael McNeal) $5,000; the board said he does not appear to hold health care licenses.

• It also imposed a $10,000 fine on Forgotten Formula, a Texas-based private membership association accused of mailing peptides into Nevada — which the board characterized as unlicensed wholesaling of drugs.

• The citations stem from July’s “Revolution Against Aging and Death Festival” (RAADFest) in Las Vegas, where two women became critically ill after peptide injections at Holtorf’s booth.

Why it Matters for Care

• Two patients required intubation after “anti-aging” peptide injections — a reminder to explicitly ask about peptides/“regenerative” injectables when evaluating unexplained respiratory failure, shock, or severe reactions after wellness events.

• The board said it could not determine whether illness was due to contamination vs. a reaction to the peptides themselves; investigators were unable to test the serums because the product could not be obtained.

• At least one injected peptide was reportedly on an FDA list of peptides that pose “significant safety risks” and are prohibited for compounding — relevant for clinicians counseling patients who assume “compounded” implies vetted or traceable supply.

• Documentation and reporting matter: adverse event reporting and careful exposure histories may be the only way to build signal when products are mailed, relabeled, or otherwise difficult to secure for testing.

Between the Lines

• Peptides sit in a regulatory gap: FDA-approved peptide drugs exist for serious diseases, but anti-aging/regenerative “cocktails” are often marketed in a gray zone that can evade pharmacy and medical practice rules.

• Private membership associations are testing a constitutional-style argument that member transactions occur “outside the scope” of state commercial regulation — potentially complicating state enforcement if the model spreads.

• Politics is close to the story: HHS Secretary Robert F. Kennedy Jr. has been a strong proponent of peptides and has said the FDA plans to reclassify 14 peptides currently listed as unsafe, which could expand what compounding pharmacies can dispense.

• Second-order effect: broader access via reclassification could normalize use faster than systems can build safety infrastructure (quality, labeling, pharmacovigilance, and clinician/patient education).

What to Watch

• Whether cited parties appeal to the Nevada Pharmacy Board, and how the board responds to the private membership association’s legal claims.

• Possible follow-on discipline by California licensing boards, which Nevada officials said were notified about the fines.

• Any FDA action tied to the case — and whether the agency advances (or delays) reclassification of the 14 peptides referenced by Kennedy.

• State-level copycat enforcement (or loophole-seeking) as wellness conferences and “anti-aging” clinics watch how Nevada handles mailed products and cross-state practice.

Source: ProPublica